Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir Parekh

Showing results (101-110 of 162) with videos related to

Pageof 17
Sort By:
American Journal of Hematology|May 14, 2026
Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple MyelomaMickael Tordjman, Anis Meribout, Amine Geahchan, et al.
Cancer Cell|July 9, 2021
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myelomaOliver Van Oekelen, Charles R Gleason, Sarita Agte, et al.
Blood Advances|January 29, 2024
Regression of smoldering myeloma with treatment of Gaucher diseaseKevin Barley, Anshuman Parekh, Syed Salam, et al.
Cell Reports. Medicine|May 22, 2024
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myelomaOliver Van Oekelen, Michael Amatangelo, Manman Guo, et al.
Science Advances|November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implicationsSherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2019
Mutation-derived Neoantigen-specific T-cell Responses in Multiple MyelomaDeepak Perumal, Naoko Imai, Alessandro Laganà, et al.
JCO Precision Oncology|February 2, 2019
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics ApproachAlessandro Laganà, Itai Beno, David Melnekoff, et al.
Blood|May 12, 2026
Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathwaysHsiling Chiu, Junfei Zhao, Tara Basavanhally, et al.
Blood Advances|January 4, 2018
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaAjai Chari, Hearn J Cho, Amishi Dhadwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2021
SOX11 Inhibitors Are Cytotoxic in Mantle Cell LymphomaShashidhar S Jatiani, Stephanie Christie, Violetta V Leshchenko, et al.
Pageof 17

Showing results (101-110 of 162) with videos related to

Sort By:
Pageof 17
American Journal of Hematology|May 14, 2026
Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple MyelomaMickael Tordjman, Anis Meribout, Amine Geahchan, et al.
Cancer Cell|July 9, 2021
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myelomaOliver Van Oekelen, Charles R Gleason, Sarita Agte, et al.
Blood Advances|January 29, 2024
Regression of smoldering myeloma with treatment of Gaucher diseaseKevin Barley, Anshuman Parekh, Syed Salam, et al.
Cell Reports. Medicine|May 22, 2024
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myelomaOliver Van Oekelen, Michael Amatangelo, Manman Guo, et al.
Science Advances|November 17, 2021
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implicationsSherry Bhalla, David T Melnekoff, Adolfo Aleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2019
Mutation-derived Neoantigen-specific T-cell Responses in Multiple MyelomaDeepak Perumal, Naoko Imai, Alessandro Laganà, et al.
JCO Precision Oncology|February 2, 2019
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics ApproachAlessandro Laganà, Itai Beno, David Melnekoff, et al.
Blood|May 12, 2026
Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathwaysHsiling Chiu, Junfei Zhao, Tara Basavanhally, et al.
Blood Advances|January 4, 2018
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaAjai Chari, Hearn J Cho, Amishi Dhadwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2021
SOX11 Inhibitors Are Cytotoxic in Mantle Cell LymphomaShashidhar S Jatiani, Stephanie Christie, Violetta V Leshchenko, et al.
Pageof 17